Welcome to our dedicated page for Deciphera Pharma news (Ticker: DCPH), a resource for investors and traders seeking the latest updates and insights on Deciphera Pharma stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Deciphera Pharma's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Deciphera Pharma's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) has announced that it will release its first quarter 2023 financial results on May 3, 2023, at 8:00 AM ET. A live conference call will follow to discuss the results and provide a corporate update. Interested parties can access the call through a designated link or via the company’s website. Deciphera focuses on developing innovative medicines for cancer patients, leveraging its proprietary switch-control kinase inhibitor platform. The company’s product, QINLOCK®, is a switch-control inhibitor approved for fourth-line treatment of GIST in several regions, including the U.S. and European Union. For more details, visit deciphera.com.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that its management will participate in a fireside chat at the Stifel Virtual Targeted Oncology Days on April 26, 2023, at 10:30 AM ET. The event aims to discuss the company's progress in developing innovative medicines for cancer treatment.
A live webcast will be accessible on the Company’s website under the “Investors” section, with an archived replay available for 90 days post-event. Deciphera's focus is on commercializing new treatments, notably QINLOCK®, a switch-control kinase inhibitor approved in multiple countries including the US, Canada, and the EU for the treatment of fourth-line GIST.
Deciphera Pharmaceuticals (NASDAQ: DCPH) announced that QINLOCK is now included in the NCCN Guidelines as a preferred regimen for second-line gastrointestinal stromal tumor (GIST) patients intolerant to sunitinib. The FDA granted Breakthrough Therapy Designation for QINLOCK, indicating its potential to improve treatment outcomes for adult patients with unresectable or metastatic GIST with specific mutations. The company plans to initiate the INSIGHT Phase 3 Study in late 2023, aimed at evaluating QINLOCK against sunitinib in similar patient populations. This follows positive results from the INTRIGUE study, demonstrating QINLOCK's efficacy and tolerability profile.